Search company, investor...

Predict your next investment

Innovation Norway company logo
Government
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Management & Strategy Consulting
innovasjonnorge.no

Investments

126

Portfolio Exits

10

Partners & Customers

7

About Innovation Norway

Innovation Norway is the Norwegian Government's most important instrument for the development of Norwegian enterprises and industry. Innovation Norway promotes nationwide industrial development to both the business economy and Norway's national economy, and helps release the potential districts and regions by contributing to innovation, internationalization and promotion.

Headquarters Location

Pb. 448 Sentrum Akersgata 13

Oslo, 0104,

Norway

+47 22 00 25 00

Want to inform investors similar to Innovation Norway about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Innovation Norway News

Circio: First patient in multiple myeloma trial dosed with TG01 at Oslo University Hospital

Jun 22, 2023

Circio Thu, Jun 22, 2023 07:00 CET TG01 monotherapy will be evaluated in 20 patients with RAS-mutated multiple myeloma. The trial is sponsored by Oslo University Hospital and led by Dr. Fredrik Schjesvold, an international leader in the field and founder of the Oslo Myeloma Center, the largest Myeloma center in the Nordics Oslo, Norway, 22 June 2023 - Circio Holding ASA (OSE: CRNA), today announces that the first multiple myeloma (MM) patient has been dosed with mutant RAS cancer vaccine TG01 at Oslo University Hospital (OUS). The study is led by multiple myeloma expert Dr. Fredrik Schjesvold in a clinical collaboration between OUS and Circio. OUS is the study sponsor, with Dr. Schjesvold as the principal investigator, in collaboration with project lead Dr Hanne Norseth and Research medical student Hedda Monsen. Circio will provide TG01 drug supply, scientific support and a financial contribution. Mutations in the RAS genes are commonly found in pancreatic cancer, colon cancer myeloma and lung cancer but outside of lung cancer there are no RAS-targeted therapies available for these patients. TG01 is a mutant RAS therapeutic cancer vaccine adjuvanted by QS-21 STIMULON, which targets the seven most commonly found RAS mutations. TG01 has previously demonstrated robust immune responses and survival benefit in resected pancreatic cancer combined with standard of care chemotherapy. In this study, TG01 vaccination will be tested as a monotherapy in 20 KRAS or NRAS mutated myeloma patients who have either high risk smoldering myeloma or have evidence of disease after completion of standard of care (SoC) therapy. The treatment period is 12 months. In the first 3 months TG01 is given every other week, and thereafter it is given once every second month for 9 months. The aim is to assess whether anti-RAS T-cell priming induced by TG01 can delay the disease progression and enhance the clinical response. Dr. Fredrik Schjesvold, Founder and Leader Oslo Myeloma Center, at Oslo University Hospital, and President of the Nordic Myeloma Study Group, said: “There are no targeted therapy options available for RAS-mutated multiple myeloma patients which continue to have a clear need for better and more tolerable treatments. I believe the TG01 vaccine has the potential to eliminate residual disease and delay recurrence following standard of care treatment, and we look forward to work with Circio to test this therapeutic concept at our center.” Margrethe Sørgaard, VP and Head of Clinical Development of Circio Holding ASA, added: “Having the first patient dosed in Dr. Schjesvold´s study in multiple myeloma is an important milestone for the TG program. It is the first time the TG01 cancer vaccine will be tested in this indication, and the first time the new and enhanced vaccine format of sub-cutaneous single-injection TG01 adjuvanted by QS-21 STIMULON has been administered to a patient in Europe. We firmly believe that TG01 can bring targeted clinical benefit, with a favorable safety profile, to this underserved area of RAS-mutated multiple myeloma.” About TG01 mutant RAS vaccine Oncogenic mutations in the RAS family of genes drive up to 30% of all cancers and remain a major unmet medical need with few good treatment alternatives. Circio was recently awarded two prestigious research grants from Innovation Norway and the Norwegian Research Council, totaling NOK 18m, to advance its TG mutant RAS cancer vaccine program. About Agenus, QS-21 STIMULON Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. In March 2022, Circio announced a collaboration with Agenus to utilize the proprietary adjuvant QS-21 STIMULON as an immune-stimulatory component of the TG vaccines for future development and commercialization. QS-21 STIMULON has consistently demonstrated powerful antibody and cell-mediated immune responses both in cancer trials and as a component of the commercial Shingrix*, Mosquirix* and Arexvy* vaccines. QS-21 STIMULON is expected to further potentiate the TG vaccines by driving stronger anti-RAS T-cell responses. *Trademarks owned by GSK. Erik Digman Wiklund, CEO Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines. Building on deep experience in RNA biology, immunotherapy and viral vector engineering, Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. The most advanced therapeutic concept, circAde, builds on the company´s experience in oncolytic viruses to use engineered adenoviruses for delivery of circRNA to cancer cells. This unique approach is the only currently known circRNA program targeting solid tumors. Circio´s strategy is to develop novel circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate our circRNA pipeline development. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden. Circio´s clinical immunotherapy programs are designed to activate the patient´s own immune system to fight cancer cells and provide benefit to patients with no or few treatment alternatives. Lead candidate ONCOS-102 is an oncolytic adenovirus (AdV5) carrying a genetic cassette for mRNA-based expression of the cytokine GM-CSF, designed to selectively target cancer cells and drive an anti-tumor immune response. ONCOS-102 has demonstrated an excellent safety profile, strong immune responses and clinical efficacy in several cancer types in Phase 1/2 studies, both as monotherapy and in combinations with checkpoint inhibitors or standard-of-care chemotherapy. Circio is aiming to progress ONCOS-102 into a phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment, subject to additional external financing and/or partnerships to support the program. Circio’s second clinical stage program is an immunotherapy targeting KRAS driver mutations. Lead candidate TG01 has previously shown robust immune responses and encouraging clinical benefit in surgically resected pancreatic cancer, and is currently being tested in two clinical trials in RAS-mutated pancreatic cancer and multiple myeloma in the USA and Norway. These studies are being run through industry and academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating broad future optionality for the TG01 program at low cost to Circio.

Innovation Norway Investments

126 Investments

Innovation Norway has made 126 investments. Their latest investment was in StepFWD as part of their Grant on August 8, 2023.

CBI Logo

Innovation Norway Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/31/2023

Grant

StepFWD

$0.22M

Yes

1

7/10/2023

Unattributed

Agder Gruppen

$1.9M

Yes

1

6/6/2023

Unattributed

Aviant

$1.07M

No

2

5/3/2023

Grant

Subscribe to see more

$99M

Subscribe to see more

10

4/26/2023

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/31/2023

7/10/2023

6/6/2023

5/3/2023

4/26/2023

Round

Grant

Unattributed

Unattributed

Grant

Grant

Company

StepFWD

Agder Gruppen

Aviant

Subscribe to see more

Subscribe to see more

Amount

$0.22M

$1.9M

$1.07M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Innovation Norway Portfolio Exits

10 Portfolio Exits

Innovation Norway has 10 portfolio exits. Their latest portfolio exit was Unite Living on September 20, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/20/2023

Asset Sale

$99M

2

7/7/2023

Corporate Majority

$99M

2

4/21/2022

Acquired

$99M

3

9/23/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/21/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/20/2023

7/7/2023

4/21/2022

9/23/2021

12/21/2020

Exit

Asset Sale

Corporate Majority

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

3

10

10

Innovation Norway Partners & Customers

7 Partners and customers

Innovation Norway has 7 strategic partners and customers. Innovation Norway recently partnered with Falck Group, Safeture, and Aeger Group on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/16/2022

Vendor

Denmark, Sweden, and Norway

COMUNICADO: Safeture partnering with Falck Global Assistance & Aeger Group wins agreement with Innovation Norway

LUND , Sweden , Aug. 16 , 2022 / PRNewswire / -- Safeture in partnership with Falck Global Assistance & Aeger Group has secured a two-year public procurement agreement regarding employee safety and travel risk management for Innovation Norway .

2

4/1/2022

Partner

Norway

Subscribe to see more

Subscribe to see more

10

4/1/2022

Partner

Norway

Subscribe to see more

Subscribe to see more

10

1/4/2022

Partner

Norway

Subscribe to see more

Subscribe to see more

10

1/4/2022

Partner

Norway

Subscribe to see more

Subscribe to see more

10

Date

8/16/2022

4/1/2022

4/1/2022

1/4/2022

1/4/2022

Type

Vendor

Partner

Partner

Partner

Partner

Business Partner

Country

Denmark, Sweden, and Norway

Norway

Norway

Norway

Norway

News Snippet

COMUNICADO: Safeture partnering with Falck Global Assistance & Aeger Group wins agreement with Innovation Norway

LUND , Sweden , Aug. 16 , 2022 / PRNewswire / -- Safeture in partnership with Falck Global Assistance & Aeger Group has secured a two-year public procurement agreement regarding employee safety and travel risk management for Innovation Norway .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Innovation Norway Team

1 Team Member

Innovation Norway has 1 team member, including former Chief Executive Officer, Anita Krohn Traaseth.

Name

Work History

Title

Status

Anita Krohn Traaseth

Chief Executive Officer

Former

Name

Anita Krohn Traaseth

Work History

Title

Chief Executive Officer

Status

Former

Compare Innovation Norway to Competitors

IAESTE Norway Logo
IAESTE Norway

IAESTE Norway is an international student organization. It represents the interests of academia, business, and students. It specializes in exchanging trainee jobs for students within technology, science, and economics in all the member countries. The organization was founded in 1948 and is based in Trondheim, Norway.

I
Innovation Centre Denmark

Innovation Center Denmark (ICDK) is a trade and development company. It provides services to companies, research and educational institutions, public stakeholders, and Danish citizens and society. It specializes in investment promotion, entrepreneurship, and collaboration in higher education, research, partnering, and assessment in science and technology. It was founded in 2006 and is based in Palo Alto, California.

I
Innovation Center for Artificial Intelligence

Innovation Center for Artificial Intelligence (ICAI) operates as a knowledge institute. It focuses on joint technology development and research between academia, industry, and government in artificial intelligence (AI). The institute was founded in 2018 and is based in Amsterdam, Netherlands.

CLEPA Logo
CLEPA

CLEPA is the European association of automotive suppliers. It represents companies supplying components and innovative technology for safe, smart, and sustainable mobility, investing over 30 billion euros a year in research and development. It was founded in 1959 and is based in Brussels, Belgium.

E
EGI Foundation

EGI Foundation operates as an information technology (IT) and consulting organization. It delivers data analytics services to support scientists, projects, research infrastructures, businesses, and many more. The organization was founded in 2010 and is based in Amsterdam, Netherlands.

Innovation Centre Denmark Logo
Innovation Centre Denmark

Innovation Centre Denmark (ICDK) connects businesses, research organisations, and higher education institutions. It offers strategic advice, funding opportunities, and other services. The organization serves life science, green transition, and technology industries. It was founded in 2006 and is based in Copenhagen, Denmark.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.